Nasospore Stent For Use in Enodscopic Sinus Surgery
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00671541 |
Recruitment Status :
Withdrawn
(Principal Investigator left the institution requested study terminated.)
First Posted : May 5, 2008
Last Update Posted : February 17, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chronic Sinusitis | Drug: Merogel Nasal Stent and Nasopore Stent Drug: Nasopore Stent and either Gentamycin or Bacitracin | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Treatment |
Official Title: | Nasospore Stent For The Use in Endoscopic Sinus Surgery |
Study Start Date : | March 2006 |
Actual Primary Completion Date : | February 2012 |
Actual Study Completion Date : | February 2012 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Merogel stent vs. Nasopore Stent
This study has two arms consiting of 50 subjects each (100 total) Arm 1 will recieve the standard stent (merogel)in their right sinus and a nasopore stent in their left sinus.
|
Drug: Merogel Nasal Stent and Nasopore Stent
Merogel Nasal Stent and Nasopore Stent
Other Names:
|
Experimental: bacitracin vs. gentamicin treated stent
The second arm will consist of 50 new subjects. These 50 subjects will have a nasopore stent placed in the left sinus. The first 25 subjects will have nasopore stent placed postoperatively with a bacitracin soaked nasopore in right sinus the second 25 will have a gentamycin soaked nasopore stent in right sinus.
|
Drug: Merogel Nasal Stent and Nasopore Stent
Merogel Nasal Stent and Nasopore Stent
Other Names:
Drug: Nasopore Stent and either Gentamycin or Bacitracin Nasopore Stent with Bacitracin (100,000 units in 10cc(NSS)or Gentamycin(80mg in 10cc NSS)
Other Names:
|
- This study will evaluate the efficacy of nasopore stent soaked in bacitracin in and one stent soaked in gentaymcin antibiotic solution [ Time Frame: prospective ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Evaluation by Otolaryngologist & determined to need endoscopic sinus surgery
- Only subjects with Bilateral disease
Exclusion Criteria:
- Pediatric subjects(under the age of 18)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00671541
United States, Massachusetts | |
Lahey Clinic, Inc | |
Burlington, Massachusetts, United States, 01805 |
Principal Investigator: | Peter J. Catalano, MD | Lahey Clinic |
Responsible Party: | Lahey Clinic |
ClinicalTrials.gov Identifier: | NCT00671541 |
Other Study ID Numbers: |
LCID 2006-026 |
First Posted: | May 5, 2008 Key Record Dates |
Last Update Posted: | February 17, 2012 |
Last Verified: | February 2012 |
Sinusitis Respiratory Tract Infections Infections Paranasal Sinus Diseases Nose Diseases Respiratory Tract Diseases Otorhinolaryngologic Diseases Gentamicins |
Bacitracin Anti-Bacterial Agents Anti-Infective Agents Protein Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Infective Agents, Local |